top of page
Revolutionizing Immune Postbiotics: RHT3201®
RHT3201® emerges as a pioneering postbiotic, uniquely approved by Korea's FDA for its immune-balancing properties. This advanced formula is clinically proven to reduce hypersensitivity and alleviate symptoms in conditions like atopic dermatitis. RHT3201® stands out as a landmark development in immune health management, offering a new perspective in treating allergies and asthma-related issues.
Unlocking New Horizons in Atopic Dermatitis Care with RHT3201® Postbiotics
Discover the transformative potential of RHT3201® in the treatment of atopic dermatitis. This landmark clinical trial showcases the effectiveness of Lactobacillus rhamnosus IDCC 3201 tyndallizate in managing symptoms and improving quality of life for children affected by this condition.
Exploring the Study
This randomized, double-blind, placebo-controlled study involved administering RHT3201 to children with moderate AD. The trial's objective was to assess RHT3201's therapeutic impact on AD symptoms and its influence on immunomodulatory mechanisms.
Discovering the Results
The study revealed significant improvements in AD symptoms in the RHT3201 group compared to the placebo, particularly in long-duration AD cases. It demonstrated a decrease in inflammatory markers like eosinophil count and IL-31 levels, indicating RHT3201's potential in AD treatment.
RHT3201®: A New Dawn in Hypersensitivity Treatment
RHT3201® encapsulates the transformative impact of this novel treatment, revealing significant improvements in managing hypersensitivity, including atopic dermatitis symptoms. The clinical trial highlights RHT3201®'s effectiveness, especially in long-term cases, alongside a strong safety profile, offering a beacon of hope for children afflicted with this challenging skin condition.
Significant Symptom Reduction
The RHT3201 study showcased a notable improvement in atopic dermatitis symptoms. Participants receiving RHT3201 experienced a more significant reduction in SCORAD scores, indicating better symptom management compared to the control group.
Enhanced Benefits for Long-term AD (Atopic Dermatitis)
For children with a longer history of atopic dermatitis, RHT3201 proved even more effective. The treatment led to a marked decrease in inflammation markers, particularly in cases lasting 50 months or more.
Assured Safety Profile
Safety is paramount in any treatment, and RHT3201 stands out for its well-established safety profile. The study confirmed its safety, making it a reliable option for managing atopic dermatitis in children.
Versatile Formulations
with Postbiotics
Explore the future of wellness through our versatile probiotic formulations, enhanced by their unique parabiotics feature. Our product range includes capsules, sticks, gummies, stick jellies, tablets, chewables, and drops, offering tailored solutions to suit your individual health and lifestyle requirements.
Capsules
Sticks
Stick Jelly
Gummies
Chewables
Soft gel
Tablets
Oil Drops
bottom of page